Targets › SOST
2 programs from 2 companies in 17 trials: 7 Phase 4, 5 Phase 3, 3 Phase 2, 2 Phase 1; Other, Neurology, Metabolic and endocrine; next expected readout Jan 2027.
Negative regulator of bone growth that acts through inhibition of Wnt signaling and bone formation. (UniProt, Q9BQB4)
Open in Phaseline: the race on SOST, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Amgen | Romosozumab Sclerostin inhibitor | SOST | Phase 3 | Osteogenesis Imperfecta; Healthy Participants; Osteoporosis; Postmenopausal Osteoporosis … | Jan 2027 |
| Ultragenyx Pharmaceutical | setrusumab Sclerostin inhibitor | SOST | Phase 3 | Osteogenesis Imperfecta | Jan 2027 |
Osteoporosis (6) Osteogenesis Imperfecta (5) Healthy Participants (1) Postmenopausal Osteoporosis (1) Osteoporosis, Postmenopausal (1) FHA (Functional Hypothalamic Amenorrhea) (1) Premenopausal Idiopathic Osteoporosis (1) Breast Cancer (1)
antibody (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.